Rheumatology, Medical Department I, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin 12203, Germany.
Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi: 10.1016/j.rdc.2012.08.005. Epub 2012 Sep 15.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first-line therapy in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine. However, effective control of symptoms and retardation of radiographic progression often require continuous and long-term treatment, which raises safety concerns. This article discusses controversies related to the current role of NSAIDs in axSpA treatment, risks and benefits of this treatment, and current trends for individualized treatment.
非甾体抗炎药（NSAIDs）被认为是轴性脊柱关节炎（axSpA）患者的一线治疗药物，包括强直性脊柱炎。NSAIDs 可有效减轻大多数患者的疼痛和僵硬，能够减轻全身和局部炎症，并能抑制脊柱结构损伤的进展。然而，要有效控制症状和延缓放射学进展，往往需要持续和长期治疗，这引发了安全性方面的担忧。本文讨论了与 NSAIDs 在 axSpA 治疗中的当前作用相关的争议、这种治疗的风险和获益，以及当前个体化治疗的趋势。
